

Booking Date	30/10/2024	Patient ID : 012410300049	Reported on 07/11/2024
Name	Archana	Age : 45 Years	Sex - Female
Ref By	Dr. Amish Vora		

DIAGNOSIS: Her2 IHC 2+ (Equivocal) Breast Cancer IDC


METHODOLOGY: Fluorescence *in situ* Hybridization (FISH)

PROBE NAME: HEALTHCARE HER2/CEP17 dual color probe.

FISH:

Total number of cells scored	100
Total number of HER2 signals	125
Total number of CEP17 signals	120
Average HER2 signals/cell	1.25
Computed Ratio	1.04

Negative



Cells showing HER2 signals (orange) and CEP17 signals (green).

CLINICAL INTERPRETATION:

1. Negative for HER2/neu amplification as per ASCO 2018 guidelines.
2. Her2:CEP17 ratio is < 2 and Average Her2 signals <4 (Group 5).

RECOMMENDATION:

Please Note: Evaluation of this specimen shows a normal hybridization pattern. These findings are indicative that the patient is not eligible for anti HER2 therapy (Trastuzumab). Her2 gene amplification is seen 18 to 20% of invasive breast cancers. These tumours show increased over all survival rate with Her2 targeted therapy such as Trastuzumab. It has been recognised as a poor prognosis indicator in early breast cancer. In cases where tumor heterogeneity is present, analysis of HER2 FISH on additional blocks is recommended for conclusive result.